Saltoro Capital’s Verve Therapeutics VERV Stock Holding History

Saltoro Capital’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-66,500	Closed	-$882K	–	58
2023 Q3	$882K	Buy	+66,500	New	+$1.07M	0.79%	25

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Saltoro Capital's VERV Position: Q4 2023 in Review

Saltoro Capital sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 66,500 shares — an estimated $882K sold.

Saltoro Capital first reported a position in VERV in Q3 2023 and held it in 1 quarter. The position peaked at $882K in Q3 2023. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

Saltoro Capital reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
Saltoro Capital sold 66,500 Verve Therapeutics shares in Q4 2023, an estimated $882K.
Saltoro Capital first reported a position in Verve Therapeutics in Q3 2023 and held it in 1 quarter.
Saltoro Capital's Verve Therapeutics position peaked at $882K in Q3 2023.
157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Saltoro Capital's 13F filing for Q4 2023, filed 14 Feb 2024.